Meeting
2023 ASCO Gastrointestinal Cancers Symposium
Costs of adverse event management associated with first-line cetuximab or panitumumab in patients with metastatic colorectal cancer in Spain.
Authors
Begoña Graña Suárez
SERGAS, A Coruna, Spain;
Begoña Graña Suárez , Noelia Tarazona , Olga Duran Moran , Ana Fernandez Gonzalez , Heidi De los Santos Real , Chris P. Pescott
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Poster Session C: Cancers of the Colon, Rectum, and Anus
Track
Colorectal Cancer,Anal Cancer
Sub Track
Quality of Care/Quality Improvement
Citation
J Clin Oncol 41, 2023 (suppl 4; abstr 83)
DOI
10.1200/JCO.2023.41.4_suppl.83
Abstract #
83
Poster Bd #
D20
Abstract Disclosures
Similar Posters
Poster
2022 ASCO Gastrointestinal Cancers Symposium
Adverse event management costs for first-line treatment with cetuximab or panitumumab of RAS wild-type metastatic colorectal cancer patients in Latin America.
First Author: Chris Pescott
Poster
2021 Gastrointestinal Cancers Symposium
Safety analysis of the randomized phase II study of FOLFOXIRI plus cetuximab versus FOLFOXIRI plus bevacizumab as the first-line treatment in metastatic colorectal cancer with RAS wild-type tumors: The DEEPER trial (JACCRO CC-13).
First Author: Takanori Watanabe
Poster
2020 Gastrointestinal Cancers Symposium
Real-world costs of cetuximab + chemotherapy administered every two weeks versus weekly for treatment of metastatic colorectal cancer.
First Author: Chris Pescott
Poster
2015 Gastrointestinal Cancers Symposium
Drug cost and outcome in metastatic colorectal cancer with emphasis on monoclonal antibodies.
First Author: Helmy M. Guirgis